Pegpleranib

Drug Profile

Pegpleranib

Alternative Names: E-10030; E01AJ; Fovista; OAP-030; Pegpleranib sodium; X01E

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Archemix Corporation
  • Developer National Eye Institute; OphthoTech Corporation
  • Class Eye disorder therapies; Oligonucleotides; Peptide aptamers
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase I/II Von Hippel-Lindau disease
  • Research Retinoblastoma

Most Recent Events

  • 14 Aug 2017 Efficacy and adverse events data from a phase III OPH 1004 trial in Wet age-related macular degeneration released by OphthoTech
  • 14 Aug 2017 OphthoTech terminates a phase III OPH 1004 trial in Wet age-related macular degeneration due to absence of clinically meaningful visual benefit in Argentina, Australia, Austria, Brazil, Canada, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Latvia, , Norway, Poland, Portugal, Slovakia, Spain, USA (Intravitreous)
  • 26 Jul 2017 Early research in Retinoblastoma in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top